Literature DB >> 6995096

The cephalosporins: activity and clinical use.

A J Weinstein.   

Abstract

The cephalosporin antibiotics have been employed with increasing frequency since their introduction into clinical practice in the early 1960s. With the exception of cephaloridine, cephalosporin compounds are not associated with the production of significant untoward effects. The availability of newer cephalosporins, both oral and parenteral, with enhanced antibacterial activity, has expanded the clinical indications for administration of these antibiotics.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6995096     DOI: 10.2165/00003495-198020020-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  113 in total

1.  CEPHALOTHIN--A NEW ANTIBIOTIC. PRELIMINARY CLINICAL AND LABORATORY STUDIES.

Authors:  R S GRIFFITH; H R BLACK
Journal:  JAMA       Date:  1964-09-14       Impact factor: 56.272

2.  CEPHALOTHIN SERUM LEVELS IN THE AZOTEMIC PATIENT.

Authors:  S A KABINS; S COHEN
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964

3.  Penicillin allergy.

Authors:  C W PARKER
Journal:  Am J Med       Date:  1963-06       Impact factor: 4.965

4.  The penetration characteristics of cefazolin, cephalothin, and cephradine into bone in patients undergoing total hip replacement.

Authors:  B A Cunha; H R Gossling; H S Pasternak; C H Nightingale; R Quintiliani
Journal:  J Bone Joint Surg Am       Date:  1977-10       Impact factor: 5.284

5.  Therapy of serious infections with cefamandole.

Authors:  M F Parry; M J Goldberger; H C Neu
Journal:  Infection       Date:  1978       Impact factor: 3.553

6.  Laboratory studies with a new cephalosporanic acid derivative.

Authors:  D R Chisholm; F Leitner; M Misiek; G E Wright; K E Price
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

7.  Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics.

Authors:  R N Jones; P C Fuchs; C Thornsberry; A L Barry; T L Gavan; E H Gerlach
Journal:  Am J Clin Pathol       Date:  1979-10       Impact factor: 2.493

8.  Concentration of cefamandole in serum interstitial fluid, bile, and urine.

Authors:  N G Waterman; H U Eickenberg; L Scharfenberger
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

9.  Clinical and laboratory evaluation of cefamandole in the therapy of Haemophilus spp. Bronchopulmonary infections.

Authors:  D G Delgado; C J Brau; C G Cobbs; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

10.  Evaluation of a new cephalosporin antibiotic, cephapirin.

Authors:  P Wiesner; R MacGregor; D Bear; S Berman; K Holmes; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

View more
  6 in total

Review 1.  Pharmacological properties of cephalosporins.

Authors:  W Christ
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 2.  Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine.

Authors:  B Tanrisever; P J Santella
Journal:  Drugs       Date:  1986       Impact factor: 9.546

3.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  [Nephrotoxicity of cefsulodin: experimental studies in animals (author's transl)].

Authors:  G Burmann; G Mertens; E Schulz; K Sack
Journal:  Infection       Date:  1981       Impact factor: 3.553

5.  Cefadroxil in the treatment of susceptible infections in infants and children.

Authors:  H Puhakka; E Virolainen
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.